TOP > 外国特許検索 > METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE AND PHARMACEUTICAL COMPOSITION FOR USE THEREIN

METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE AND PHARMACEUTICAL COMPOSITION FOR USE THEREIN NEW

外国特許コード F180009499
整理番号 (S2017-0113-N0)
掲載日 2018年11月1日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2017JP043034
国際公開番号 WO 2018101398
国際出願日 平成29年11月30日(2017.11.30)
国際公開日 平成30年6月7日(2018.6.7)
優先権データ
  • 特願2016-234062 (2016.12.1) JP
発明の名称 (英語) METHOD FOR TREATING INFLAMMATORY BOWEL DISEASE AND PHARMACEUTICAL COMPOSITION FOR USE THEREIN NEW
発明の概要(英語) The present invention provides a pharmaceutical composition for use in the treatment or prevention of inflammatory bowel disease (IBD). More particularly, the present invention provides a pharmaceutical composition that contains apelin or an apelin receptor agonist. The pharmaceutical composition containing apelin or an apelin receptor agonist can also be useful for the treatment of other diseases caused by inflammatory macrophages, e.g., collagen diseases.
従来技術、競合技術の概要(英語) BACKGROUND ART
Inflammatory bowel disease (Inflammatory Bowel Disease, hereinafter, simply referred to as' IBD '.) Is, such as the small intestine and large intestine mucosa of the gut of refractory chronic inflammation leads to ulceration and inflammatory disease follows a path, not the details of their etiology is known (for example, see Non-Patent Document 1).In this IBD is in a narrow sense, the large intestine mucosa sores and ulcers form the main cause of the unknown non-inflammatory diffuse ulcerative colitis exhibit, and the entire gastrointestinal tract of all layers with non-Wegener induced inflammatory, abscess or ulceration, fibers, they also cause such as a fistula or a stenosis 2 in Crohn's disease disorders.Once thought European disease in the patient is IBD japan continues to increase in recent years, ulcerative colitis, Crohn's disease in accordance with the current up to 17 million.In particular many young onset of the order of 10-20, who relapse and repeated development, academic, employment, pregnancy, such as a great influence on the child.The current is not the complete therapy, the patient may be forced over the lifetime duration of treatment, physical, mental, social, and economic burden is intractable to being tormented.
Pathogenesis of IBD is still in its condition and not yet been elucidated, tumor necrosis factor (hereinafter, referred to as' TNF '.) Such as macrophage migration inhibitory factor and, the onset or relapse of the various inflammatory mediators, and prolonged, can be involved in a severe revealed (for example, see Non-Patent Document 2 to 5).
IBD to as the main treatment options at the present time, 5-amino acid simply (5-aminosalicylic acid, '5-ASA' is called.) Formulation, steroid formulations, immunomodulatory agents and the like.But are resistant to the treatment of a patient who presents with a large number of difficult and removal, treatment over a long-term serious problem.Recently, a new anti-TNF monoclonal antibody preparation treatment method has been developed (for example, see Non-Patent Document 6 and 7).This treatment is to suppress the activity of TNF, ulcerative colitis and Crohn's disease in a patient suffering from inflammation is rapidly improved to the expected effect.However this treatment also becomes invalid or the secondary resistance and cases, such as tuberculosis infection of the malignant tumor such as malignant lymphoma and the like have frequently develop serious side effects (for example, see Non-Patent Document 8 and 9), anti-TNF antibody treatment thereof and make it difficult to continue.Therefore there is an urgent need for development of new therapy IBD is, suppression of the immune response of a particular systemic treatment method is different from the current, specific therapeutic target condition that the selected strategy is considered to be essential in the future.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
  • 発明者(英語)
  • Mori Watanabe
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記問合せ先にご相談下さい。

PAGE TOP

close
close
close
close
close
close